Moderna, Inc. (BCBA:MRNA)
Argentina · Delayed Price · Currency is ARS | Market Cap | 37.91T +188.6% |
| Revenue (ttm) | 3.30T -27.6% |
| Net Income | -4,668.21B |
| EPS | -11,863.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,199 |
| Open | 5,235.00 |
| Previous Close | 5,280.00 |
| Day's Range | 5,200.00 - 5,325.00 |
| 52-Week Range | 1,670.00 - 7,210.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
This new kind of flu shot by Moderna has just been approved by the FDA
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufactur...
Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal
Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Fo...
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future
Moderna's mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
Sandisk, AppLovin, Moderna, and More Stocks That Explain Today's Market
Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market's sky-high expectations.
FDA Approves First mRNA Flu Vaccine For Older Adults
"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Modern...
The Food and Drug Administration approved Moderna's mRNA flu vaccine, the first of its kind, capping a review that nearly collapsed in February.
The decision caps a seven-month review that included a rare refusal to consider the shot at all.
US FDA approves first mRNA flu shot from Moderna
The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for s...
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswir...
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and cu...
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collab...
Moderna Earnings Call Transcript: Q2 2026
Q2 2026 revenue exceeded guidance at $145 million, with improved cost discipline and a net loss of $782 million. Pipeline advanced with key regulatory milestones in flu and RSV vaccines, and oncology programs showed durable benefit. Revenue growth of up to 10% is expected for 2026.
Moderna Earnings release: Q2 2026
Moderna released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Moderna Slides: Q2 2026
Moderna has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
Moderna Quarterly report: Q2 2026
Moderna has published its Q2 2026 quarterly earnings report on July 31, 2026.
Moderna Narrows Loss, Says New Norovirus Vaccine Didn't Meet Expectations
Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
The drugmaker's top line continues to be heavily influenced by Covid vaccine sales.
Moderna misses quarterly revenue estimates on COVID vaccine weakness
Moderna missed Wall Street estimates for second-quarter revenue on Friday, hit by weaker-than-expected sales of its COVID-19 shot, ahead of an upcoming regulatory decision for its experimenta...
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense...
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cance...
Moderna wins EU contract for RSV vaccine supply
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report it...
Moderna Appoints Michael McDonnell to Board of Directors
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today...
Moderna stock jumps as pipeline progress and flu shot data lift sentiment
Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company among the top performers in the S&P 500 as investors responded positively to new pipeline updates, encouraging influe...